The Food and Drug Administration didn't improperly approve 11 generic versions of AstraZeneca's Seroquel in March, according to a ruling by U.S. District Judge Beryl Howell of the District of Columbia. Sales of the drug--which is used to treat schizophrenia and bipolar disorder--topped $3 billion in the U.S. last year.
AstraZeneca and Covington Fail Again in Effort to Stop Generic Seroquel
The Litigation Daily
July 6, 2012
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.